Antiproliferative immunosuppressants (Formulary)

Important: Therapy notes

Azathioprine is also used in:

• inflammatory bowel disease (Chronic bowel disorders)
• rheumatic disease (Drugs used in rheumatic diseases and gout)
• myasthenia gravis (Drugs used in neuromuscular disorders); see also Myasthenia gravis: association of British neurologists’ management guidelines at http://pn.bmj.com/content/15/3/199.full
• eczema (Preparations for eczema and psoriasis).

For advice on monitoring azathioprine refer to DMARD monitoring.

Important: Therapy notes

Be aware of the risk of pulmonary complications (bronchiectasis, pulmonary fibrosis) with mycophenolate.
MHRA advice: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients (February 2018) (www.gov.uk).
MHRA advice: Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis (January 2015) (www.gov.uk).
Mycophenolate mofetil is also used in rheumatic disease (Drugs used in rheumatic diseases and gout).  For advice on monitoring mycophenolate mofetil refer to DMARD monitoring.

Risk minimisation materials

Important: Therapy notes

• Be aware of the risk of pulmonary complications (bronchiectasis, pulmonary fibrosis) with mycophenolate.
• Mycophenolic acid is also used in rheumatic disease (Drugs used in rheumatic diseases and gout).
• For advice on monitoring mycophenolic acid refer to DMARD monitoring.
  MHRA advice: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients (February 2018) (www.gov.uk).
  MHRA advice: Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis (January 2015) (www.gov.uk).
  
  Risk minimisation materials